Year None202220212020201920182017 Jan 07, 2022 F-star Therapeutics to Participate in Upcoming Investor Conferences PDF Version Jan 05, 2022 F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration PDF Version Dec 07, 2021 F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021 PDF Version Nov 29, 2021 F-star Therapeutics to Host Virtual R&D Day on December 6, 2021 PDF Version Nov 12, 2021 F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference PDF Version Nov 10, 2021 F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update PDF Version Nov 01, 2021 F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021 PDF Version Oct 20, 2021 F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics PDF Version Sep 16, 2021 F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021 PDF Version Sep 09, 2021 F-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next
